Resistant GIST and redefining the role of F18 FDG PET

  • Ajit Sugunan Shinto, MBBS, DRM, DNB, MNAMS, PGDHA Amala Hospital, Amalanagar, Thrissur, Kerala
  • C D Joseph Amala Hospital, Amalanagar, Thrissur, Kerala
  • T J Anilkumar Amala Medical College, Thrissur
Keywords: GIST, Imatinib, Targeted molecular drugs

Abstract

We herein explore the potential additional value of F18 FDG PET scans in the management of GIST, given the prompt metabolic response to targeted molecular therapeutic drug – Imatinib and newer drugs. Literature review on the molecular pathogenesis of the primary tumor and primary and secondary resistance to Imatinib therapy could pave the way for the potential use of F18 FDG PET scan in assessing and predicting early metabolic response, acquired resistance and prognostication in these tumors. This report highlights the various areas of clinical potential and the need for prospective studies to redefine and extend the role of F18 FDG PET scans in GIST.

Author Biographies

Ajit Sugunan Shinto, MBBS, DRM, DNB, MNAMS, PGDHA, Amala Hospital, Amalanagar, Thrissur, Kerala

Nuclear Medicine Department

C D Joseph, Amala Hospital, Amalanagar, Thrissur, Kerala

Department of Oncology

T J Anilkumar, Amala Medical College, Thrissur

Associate Professor, Department of Oncology

Published
2011-12-30
How to Cite
Shinto, A., Joseph, C., & Anilkumar, T. (2011). Resistant GIST and redefining the role of F18 FDG PET. Kerala Medical Journal, 4(4), 129-131. https://doi.org/10.52314/kmj.2011.v4i4.243